obesity research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
== Effects == Lean produces mild-to-moderate "euphoric side effects" accompanied by "motor-skill impairment, lethargy, drowsiness, and a dissociative feeling from all other parts of the body." It has been suggested that the super-sweet combination of soda, cough syrup, and Jolly Ranchers provides a pleasing flavor and mouthfeel that lingers on the user's tongue for an extended duration. This phenomenon is often appealing to first-time users. Lean is often used in combination with alcohol, smoked cannabis or other recreational drugs.
== External links == Clinical trial number NCT04501666 for "Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov Clinical trial number NCT04501679 for "A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov Clinical trial number NCT03985943 for "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" at ClinicalTrials.gov Clinical trial number NCT03989349 for "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" at ClinicalTrials.gov
Singapore — The death penalty: A hidden toll of executions from Amnesty International The Singapore Government's Response To Amnesty International's Report from 30 January 2004 Asia Death Penalty monitors the death penalty in Asia, including in Singapore Singapore: Death Penalty Worldwide Academic research database on the laws, practice, and statistics of capital punishment for every death penalty country in the world.
Sources: en.wikipedia.org
Peyronie's disease diagnosis is mostly clinical. Patient history and physical examination are crucial. The most prominent features are acquired penile curvature, palpable plaques, erectile dysfunction, and pain during erections. Penile ultrasonography is the imaging method of choice for plaque location, measurement, and confirmation of calcification. Doppler ultrasound can be utilized to assess vascular function, which is useful in the evaluation of associated erectile dysfunction. Imaging also helps to differentiate Peyronie's disease from congenital penile curvature, penile fracture, or neoplastic disease. MRI can be employed in severe ones, although it is generally not required.
== Function == Gamma-glutamyltransferase is a membrane-associated protein involved in both glutathione metabolism and the transpeptidation of amino acids. Changes in gamma-glutamyltransferase activity may signal preneoplastic or toxic conditions in the liver or kidney. The protein encoded by this gene is similar in sequence to gamma-glutamyltransferase, but its function is unknown.
=== Availability/affordability === Infliximab is supplied as a sterile, white, lyophilized (freeze-dried) powder, so must be reconstituted and administered by a health care professional, usually in a hospital or office setting. For this reason, it is usually covered under major medical insurance rather than prescription drug coverage. The loading regimen for all approved indications occurs at weeks 0, 2, and 6 at the above dosages. In the UK, infliximab is available from the NHS for Crohn's disease treatment provided three criteria are met. Patients should have severe active Crohn's disease with a CDAI score of 300 or more, have not responded to immunomodulating drugs and corticosteroids, and for whom surgery is inappropriate. Since February 2015, it is also approved for the treatment of ulcerative colitis where other treatments have not worked. In Australia, infliximab is available through the PBS for Crohn's disease treatment provided the patient has not responded to conventional treatment and has a severe case of the condition. Johnson & Johnson reported in its 2013 annual report, "Remicade (infliximab), accounted for approximately 9.4% of the Company's total revenues for fiscal 2013." A self-injectable, subcutaneous version of infliximab, Zymfentra, was approved for medical use in the United States in October 2023.
Sources: en.wikipedia.org
"Insulinoma induced hypoglycemia in a type 2 diabetic patient". Wiener Klinische Wochenschrift. 113 (9): 339–41. PMID 11388080. Janez, A. (2000). "The osmotic shock-induced glucose transport pathway in 3T3-L1 adipocytes is mediated by Gab-1 and requires Gab-1 associated phosphatidylinositol 3-kinase activity for full activation". Journal of Biological Chemistry. 275 (35): 26870–6. doi:10.1074/jbc.M001654200. PMID 10842168. Janez, A.; Worrall, DS; Olefsky, JM (2000). "Insulin-Mediated Cellular Insulin Resistance Decreases Osmotic Shock-Induced Glucose Transport in 3T3-L1 Adipocytes". Endocrinology. 141 (12): 4657–63. doi:10.1210/endo.141.12.7801. PMID 11108280.
=== Effects of Temperature === All enzymes work within a range of temperature specific to the organism. Increases in temperature generally lead to increases in reaction rates. There is a limit to the increase because higher temperatures lead to a sharp decrease in reaction rates. This is due to the denaturating (alteration) of protein structure resulting from the breakdown of the weak ionic and hydrogen bonding that stabilize the three-dimensional structure of the enzyme active site. The "optimum" temperature for human enzymes is usually between 35 and 40 °C. The average temperature for humans is 37 °C. Human enzymes start to denature quickly at temperatures above 40 °C. Enzymes from thermophilic archaea found in the hot springs are stable up to 100 °C. However, the idea of an "optimum" rate of an enzyme reaction is misleading, as the rate observed at any temperature is the product of two rates, the reaction rate and the denaturation rate. If you were to use an assay measuring activity for one second, it would give high activity at high temperatures, however if you were to use an assay measuring product formation over an hour, it would give you low activity at these temperatures.
recent surgery (both for thromboembolism and air embolism) previous stroke or cardiovascular disease a history of long-term intravenous therapy (for air embolism) Bone fracture (for fat embolism) A septal defect of the heart makes it possible for paradoxical embolization, which happens when a clot in a vein enters the right side of the heart and passes through a hole into the left side. The clot can then move to an artery and cause arterial embolisation.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.